Zevra Therapeutics Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Neil McFarlane
Chief executive officer
US$3.4m
Total compensation
| CEO salary percentage | 4.6% |
| CEO tenure | 1.3yrs |
| CEO ownership | n/a |
| Management average tenure | 1.7yrs |
| Board average tenure | 1.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$90m |
| Jun 30 2024 | n/a | n/a | -US$67m |
| Mar 31 2024 | n/a | n/a | -US$49m |
| Dec 31 2023 | US$3m | US$158k | -US$46m |
Compensation vs Market: Neil's total compensation ($USD3.45M) is above average for companies of similar size in the German market ($USD1.01M).
Compensation vs Earnings: Insufficient data to compare Neil's compensation with company performance.
CEO
Neil McFarlane (51 yo)
1.3yrs
Tenure
US$3,445,231
Compensation
Mr. Neil F. McFarlane serves as President & Chief Executive Officer at Zevra Therapeutics, Inc. since October 10, 2023 and serves as its Director since October 9, 2023. He served as Independent Director at...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.3yrs | US$3.45m | no data | |
| CFO, Secretary & Treasurer | 9.7yrs | US$2.26m | 0.035% € 140.6k | |
| Chief Commercial Officer & Executive VP of Business Development | 2.1yrs | US$1.82m | 0.0066% € 26.7k | |
| Vice President of Investor Relations & Corporate Communications | 2.5yrs | no data | no data | |
| Chief Legal Officer | less than a year | no data | no data | |
| Chief People Officer | less than a year | no data | no data | |
| Senior Vice President of Manufacturing | 2.1yrs | no data | no data | |
| Senior Vice President of Clinical Development | 2.1yrs | no data | no data | |
| Senior Vice President of Medical Affairs & Advocacy | 2.1yrs | no data | no data | |
| Chief Medical Officer | 1.1yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs & Quality | 1.1yrs | no data | no data | |
| Senior VP & Chief of Staff | 1.1yrs | no data | no data |
1.7yrs
Average Tenure
51.5yo
Average Age
Experienced Management: 1GDA's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.3yrs | US$3.45m | no data | |
| Independent Director | 1.8yrs | US$274.00k | 0% € 0 | |
| Independent Director | 1.8yrs | US$258.02k | 0% € 0 | |
| Independent Chair | 3.5yrs | US$324.39k | 0.0014% € 5.5k | |
| Member of Scientific and Medical Advisory Board | no data | no data | no data | |
| Independent Director | 1.8yrs | US$264.31k | 0.056% € 228.5k | |
| Independent Director | 1.8yrs | US$260.67k | 0.0028% € 11.4k | |
| Chairman of Scientific and Medical Advisory Board | 18.1yrs | no data | no data | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Co-Chair of Physician Advisory Council | 11.3yrs | no data | no data | |
| Co-Chair of Physician Advisory Council | 11.3yrs | no data | no data | |
| Independent Director | 1.5yrs | US$243.04k | 0.037% € 152.3k |
1.8yrs
Average Tenure
58yo
Average Age
Experienced Board: 1GDA's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/03 00:15 |
| End of Day Share Price | 2025/02/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zevra Therapeutics, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dewey Steadman | Canaccord Genuity |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Louise Chen | Cantor Fitzgerald & Co. |